How Roche, Bristol-Myers and Pfizer use M&A to strengthen their patent positions
The pharmaceutical sector has always been hot on dealmaking and the most active players continue to make serious portfolio gains in terms of volume and quality
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.